Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

The sarcopenia market size shall grow during the forecast period (2025–2034) due to the launch of upcoming therapies and the ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Two female lambs were born to a single recipient female at Srinagar’s Sher-e-Kashmir University of Agricultural Sciences and ...

Pfizer has started phase II trials of a candidate drug to treat Duchenne muscular dystrophy (DMD) as it plays catch-up with rivals PTC Therapeutics, Prosensa and Sarepta. The pharma giant has ...

No subjects experienced serious adverse events (SAEs) or discontinuations considered to be related to apitegromab treatment, ... subcutaneous myostatin inhibitor that has high in vitro affinity for ...

Roche’s decision comes after Pfizer said it was ending work on its antibody-based myostatin inhibitor domagrozumab (PF-06252616) last year after disappointing results in the muscle-wasting disease.

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at ...

Newly released video appears to show the man arrested on suspicion of murder for the death of an innocent bystander at a “No Kings” protest in Salt Lake City walking away with his rifle ...

Free Spins No Deposit - Win Real Money with oddschecker! With so many options available, we’ve taken a closer look at the best online casinos in the UK that provide free spins, both with and without ...

Reuters. FILE PHOTO: Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023, after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly ...